Sorrento plans phase II trial for COVID-19 treatment

By The Science Advisory Board staff writers

July 20, 2020 -- Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.

The tyrosine kinase inhibitor, licensed from Acea Therapuetics, is a potent immunomodulator that inhibits pro-inflammatory cytokine production, including interleukin 1 beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF alpha). These cytokines have been associated with cytokine storms and COVID-19 progression with poor outcomes in patients with acute respiratory distress syndrome (ARDS).

The phase II, double-blind, randomized clinical study (NCT04440007) will be initially conducted in the U.S.

Abivertinib has previously been studied in over 600 patients with various oncologic indications.

Sorrento moves forward with COVID-19 prophylactic drug
Sorrento has completed preclinical testing of STI-4398 (COVIDTRAP), reporting positive results on the protein's ability to neutralize and inhibit the...
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter